Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care

Olivier S. Descamps¹ | Uwe Fraass² | Ricardo Dent³ | Winfried März⁴,⁵,⁶ | Ioanna Gouni-Berthold⁷

¹Department of Internal Medicine, Centres Hospitaliers Jolimont, Haine Saint-Paul, Belgium
²Amgen GmbH, Munich, Germany
³Amgen (Europe) GmbH, Zug, Switzerland
⁴Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Graz, Austria
⁵Medical Clinic V (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
⁶Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim and Augsburg, Germany
⁷Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Cologne, Germany

Correspondence
Olivier S. Descamps, Department of Internal Medicine, Centres Hospitaliers Jolimont, Haine Saint-Paul, Belgium.
Email: olivierdescamps@hotmail.com

Present address
Ricardo Dent, Esperion Therapeutics Inc., Ann Arbor, MI, USA

Funding information
Amgen (Europe) GmbH

Summary

Objectives: To put data from our recent systematic review of phase 3 studies of anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies into the context of clinical practice.

Methods: Data from studies previously identified by a systematic review of phase 3 studies of alirocumab and evolocumab and additional references from non-systematic literature searches were used. We evaluated the hypothetical cardiovascular (CV) benefit in cases of typical patients in whom anti-PCSK9 antibodies may be recommended, using preliminary major CV event (CVE) rates from long-term clinical trials of anti-PCSK9 antibodies and from extrapolations derived from correlation between low-density lipoprotein cholesterol (LDL-C) reduction and CV benefit with other lipid-lowering therapies (LLTs).

Results: Rapid (within 1-2 weeks) and persistent (8-74 weeks) reductions in LDL-C levels were achieved with anti-PCSK9 antibodies. When combined with statins (± ezetimibe), high rates of LDL-C goal achievement were observed (41%-87% with alirocumab and 63%-100% with evolocumab). In long-term alirocumab and evolocumab studies, reductions in major CVEs of 48% and 53%, respectively, were observed. For every 38.7 mg/dL (1 mmol/L) reduction in LDL-C, a 22% reduction in relative CVE risk is predicted. Applying these assumptions to typical patients who have high–very high risk (15%-60% absolute 10-year CVE risk) and elevated LDL-C despite maximally tolerated statins, the 10-year number needed to treat with an anti-PCSK9 antibody to prevent one additional CVE varies from 4 to 26, depending on baseline LDL-C levels and residual absolute CVE risk.

Conclusions: Anti-PCSK9 antibodies effectively lower LDL-C levels in a broad patient population. While awaiting comprehensive data from CV outcome trials, these agents should be considered in very high risk patients, such as those in secondary prevention and those with familial hypercholesterolaemia who are already receiving maximally tolerated LLTs, have not achieved their LDL-C goal and require substantial reductions in LDL-C.
Cardiovascular (CV) disease (CVD) is a major cause of death worldwide; in 2012, 17.5 million people died as a result of CVD. While increasing age, male gender and unfavourable genes are non-modifiable risk factors for cardiovascular events (CVEs), hypercholesterolaemia is a major modifiable risk factor that can be corrected by reducing low-density lipoprotein cholesterol (LDL-C) levels. It has been shown that decreasing LDL-C levels is an effective way to lower CV risk.

The Sixth Joint Task Force of the European Society of Cardiology proposes LDL-C goals that are dependent on overall CVE risk; for patients with very high, high and moderate CVE risk, LDL-C goals of <70 mg/dL (<1.8 mmol/L), <100 mg/dL (<2.6 mmol/L) and <115 mg/dL (<3.0 mmol/L), respectively, are recommended. Reductions in LDL-C of at least 50% should be achieved in patients at very high and high CV risk when baseline LDL-C values in drug-naive patients are between 70 and 135 mg/dL (1.8-3.5 mmol/L) and 100 and 200 mg/dL (2.6-5.1 mmol/L), respectively. In order to achieve these goals, European guidelines for the management of hypercholesterolaemia recommend lifestyle changes such as dietary modifications and weight loss as initial measures. Even after dietary adjustments, however, LDL-C goals are often not attained. For patients who have continually elevated LDL-C levels, statins are recommended as a first-line therapeutic intervention, and as a second line, the cholesterol absorption inhibitor ezetimibe and bile sequestrants can be added to statins. However, these therapies may not be sufficient in all patients. In a study in 2012, almost half of patients with hypercholesterolaemia in Europe and Canada did not achieve their LDL-C goals, despite receiving statins. This may be due to the fact that some patients are statin-intolerant and stop taking their medication. Additionally, some patients may have very high baseline LDL-C concentrations and the maximum tolerated statin dose is insufficient to reduce LDL-C to goal levels; therefore, alternative lipid-lowering therapies (LLTs) may be needed in certain individuals. Long-term persistence with statins is important for efficacy; however, 50% or more of patients discontinue statin treatment within 1 year of initiation.

A new target for LDL-C lowering is the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 binds to the receptor for LDL (unbound or bound with LDL-C) in the liver, and this complex is endocytosed and targeted to the lysosome, rather than recycled back to the cell surface. This reduces the number of available LDL receptors and increases circulating LDL-C levels (Figure 1). Monoclonal antibodies to PCSK9 can inhibit this interaction by binding to circulating PCSK9, meaning that LDL receptors are not degraded and are therefore available to bind LDL particles and promote their removal from the circulation.

In 2015, the first anti-PCSK9 antibodies, alirocumab and evolocumab, were approved for use in Europe and the USA. This review discusses the implications of using these new agents in clinical practice by using data on their efficacy and safety as reported in studies previously identified by our systematic review of phase 3 studies of anti-PCSK9 antibodies in patients with hypercholesterolaemia. To put the efficacy data from phase 3 clinical studies into the context of clinical practice, hypothetical case studies are discussed, together with safety data from LLTs.

### 2 | METHODS

The previous systematic review identified 12 phase 3 studies of alirocumab and 9 phase 3 studies of evolocumab, together including more than 10,000 patients with elevated cholesterol levels (and hence, increased CV risk). Additional references were identified from non-systematic literature searches. No head-to-head trials have compared the efficacy and safety of alirocumab and evolocumab.

Therefore, the current review used data from the identified studies to analyse reductions in LDL-C, rates of LDL-C goal achievement and rates of adverse events (AEs). As a measure of the efficacy of these agents in clinical practice, we calculated the number needed to treat (NNT), using the following formula:

$$\text{NNT for 10 years to prevent one CVE} = \frac{100}{\ln(1 - X^\text{n})}$$

where $n$=LDL-C reduction in mmol/L and $X$ represents the hazard ratio of CVE risk for each 1 mmol/L reduction in LDL-C.

Number needed to treat values were rounded up to the nearest whole figure to avoid overestimating effectiveness. In a large meta-analysis of data from clinical trials of statins (with a follow-up of 5 years), the Cholesterol Treatment Trials’ (CTT) collaboration estimated that $X$, the hazard ratio of CVE risk for each 1 mmol/L reduction in LDL-C, to be 0.78. Data from the IMPROVE-IT trial also showed that the LDL-C reduction associated with the addition of ezetimibe to statins followed the same correlation. In both treated and untreated non-elderly individuals, the incidences of CVEs and CVE-related mortality are linear over time, as demonstrated in the 20-year follow-up.
of the West of Scotland Coronary Prevention Study (WOSCOP)\textsuperscript{22} and in the Scandinavian simvastatin survival study (4S; up to 8 years follow-up).\textsuperscript{23} It is therefore currently accepted to use the same reduction in relative risk to calculate NNTs over different time periods\textsuperscript{19,24,25}; a follow-up period of 10 years was used in the our paper. When considering the NNT estimates in our paper, it is important to note that the populations included in the CTT analysis differ slightly from those enrolled in the anti-PCSK9 trials. Moreover, the recently published FOURIER study provides evidence for a delay in the onset of risk reduction with evolocumab.\textsuperscript{26} Hence, the NNT estimations presented here may be overestimated.

3 | RESULTS

3.1 | LDL-C reductions with alirocumab and evolocumab in different patient populations

Among patients with hypercholesterolaemia or mixed dyslipidaemia, rapid (within 1-2 weeks) and persistent (20-74 weeks with alirocumab\textsuperscript{27-35} and 8-38 weeks with evolocumab\textsuperscript{36-42}) reductions in LDL-C and total cholesterol, compared with the control arms of clinical trials, were achieved with alirocumab and evolocumab.\textsuperscript{18} The LDL-C reductions in patients with hypercholesterolaemia or mixed dyslipidaemia with alirocumab or evolocumab monotherapy were 45.0%-47.2% and 56.1%-57.0%, respectively.\textsuperscript{18} In most studies, anti-PCSK9 antibodies were used in combination with other LLTs (statins and/or ezetimibe). LDL-C reductions of 45.7%-57.9% were observed with alirocumab, and 59.2%-76.3% with evolocumab in patients with hypercholesterolaemia.\textsuperscript{18} For patients with heterozygous familial hypercholesterolaemia (HeFH), LDL-C reductions ranged from 45.7% to 57.9% with alirocumab, and from 55.7% to 61.3% with evolocumab.\textsuperscript{18} Evolocumab has been investigated in patients with homozygous familial hypercholesterolaemia (HoFH), but alirocumab has not. HoFH is a rare but serious genetic disorder, and in these patients baseline LDL-C levels can be very high (greater than 500 mg/dL [12 mmol/L]); therefore, management of LDL-C is extremely challenging. Mean reductions in LDL-C with evolocumab in patients with HoFH ranged from 18.6% to 23.4%, which is less than in HeFH.\textsuperscript{39,43} Anti-PCSK9 antibodies are also effective in LDL-C lowering in patients with type 2 diabetes mellitus: pooled analyses of clinical trials of alirocumab or evolocumab in these patients revealed mean LDL-C reductions of 58.3% and 60% compared with placebo, respectively.\textsuperscript{44,45}

For patients with high and very high CV risk (excluding those with HoFH), alirocumab and evolocumab treatment resulted in mean LDL-C reductions of 44.1%-61.0% and 55.7%-75.9%, respectively.\textsuperscript{18} In patients with moderate to very high CV risk receiving alirocumab, LDL-C reductions of 47.2%-58.7% were observed.\textsuperscript{18} For those with low to high CV risk, evolocumab treatment reduced mean LDL-C levels...
by 53.3%-64.0%. Anti-PCSK9 antibodies can also induce substantial reductions in LDL-C in patients who are statin-intolerant: mean reductions of 45.0% and 55.3%-56.1% were observed in studies of alirocumab and evolocumab, respectively.2,42

These data illustrate consistently large reductions in LDL-C levels with anti-PCSK9 antibodies across patient groups, regardless of baseline LDL-C levels and background LLT. In addition, a meta-analysis of 25 randomised controlled trials of anti-PCSK9 antibodies reported slightly better efficacy in terms of LDL-C lowering with evolocumab than with alirocumab.46 While the favourable effects of evolocumab and alirocumab were observed largely in patients receiving background statin treatment, such effects were also seen in patients not receiving additional LLTs.46 Therefore, background statin use appears to contribute to LDL-C lowering to a minor degree only, with consistent LDL-C reductions observed across groups, regardless of background LLT.18

Substantial, but transient, LDL-C reductions can be achieved using lipoprotein apheresis in patients with HeFH,47 and there are data from patients with HeFH that show that switching from apheresis to evolocumab is effective in maintaining the LDL-C-lowering effect of apheresis.48 A small population of LLT-intolerant patients with elevated LDL-C levels may be eligible for apheresis. This procedure is widely used in Germany, but less so in other European countries and the USA.49 Anti-PCSK9 antibodies could replace apheresis in some patients: 48-week treatment with evolocumab (420 mg every 2 weeks) in 34 patients with HeFH resulted in 21% reduction in mean LDL-C and 15% of patients stopping or reducing the frequency of apheresis.50 A phase 3 randomised study in 62 patients with HeFH undergoing regular apheresis therapy found that alirocumab (150 mg every 2 weeks) reduced the need for apheresis by 75% from week 7 to 18; apheresis was stopped in 63.4% of patients.51 At week 18, mean LDL-C reductions from baseline were 42.5% in the alirocumab group vs 1.6% in the placebo group.51 How these data will translate into clinical practice is under debate; less than half of patients had not exhausted all statin options before enrolling in the study and apheresis was stopped once patients’ LDL-C levels were at least 30% lower than at pre-apheresis baseline, which may not be sufficient to achieve LDL-C goal among patients very high LDL-C levels at baseline.52 Notwithstanding, German reimbursement rules currently in place require initiation of anti-PCSK9 antibodies before approval of apheresis treatment. This is legitimate since PCSK9 inhibition may result in improved quality of life at significantly lower costs compared with apheresis.48 A phase 3 randomised study assessing evolocumab compared with apheresis in patients with hypercholesterolaemia who were already receiving LDL-C apheresis is ongoing (NCT02585895).

3.2 LDL-C goal achievement with alirocumab and evolocumab in different patient populations

In the included studies, goal achievement was measured according to the 2011 European Atherosclerosis Society/European Society of Cardiology guidelines (<70 mg/dL [1.8 mmol/L] for patients at very high CV risk or <100 mg/dL [2.6 mmol/L] for patients at high CV risk).18,53 High rates of LDL-C goal achievement were observed when an anti-PCSK9 antibody was combined with a statin: 41.0%-87.2% with alirocumab plus statin and 63.0%-100% with evolocumab plus statin.18 Goal achievement with monotherapy was also high: 42.0%-65.0% with alirocumab and 69.0%-84.0% with evolocumab.18 Overall, there was an apparent inverse relationship between baseline LDL-C level and the proportion of patients achieving their LDL-C goals.18 In most studies, LDL-C goals were achieved by a large proportion of patients, regardless of the presence of comorbidities, type 2 diabetes mellitus, HeFH and CVD; and irrespective of baseline characteristics such as age, gender and use (and dose) of statin or other LLT.18

Table 1 provides an overview of the proportion of patients achieving LDL-C goals according to baseline characteristics. For patients with HeFH, 72.2%-81.4% of patients achieved their goals with alirocumab, and 63.0%-68.0% with evolocumab.18 In another study of patients with HeFH and high CV risk, 41.0% of patients achieved their LDL-C goal.54 In studies of patients with HoFH the proportions of patients achieving their LDL-C goals were not reported. A meta-analysis of patient data from individuals with type 2 diabetes mellitus receiving evolocumab found that goal achievement was 87.0%-88.0%.45 Goal achievement was not reported for similar alirocumab studies. The high proportion of patients with type 2 diabetes mellitus achieving their LDL-C goals may relate to the fact that baseline LDL-C levels in these patients is slightly lower than in those without type 2 diabetes mellitus.

For patients with high LDL-C at baseline (≥3.5 mmol/L [≥135 mg/dL]; excluding those with FH), goal achievement was reported in 64.0%-87.2% of patients receiving alirocumab.18 In the YUKAWA-1 study, 96%-100% of patients with high LDL-C at baseline achieved their LDL-C goals with evolocumab.56,57 Almost half (42.0%-45.5%) of statin-intolerant patients achieved their LDL-C goals with alirocumab or evolocumab.18

3.3 Safety data for anti-PCSK9 antibodies and other LLTs

Musculoskeletal events feature strongly in the adverse event (AE) profiles of LLTs. Rhabdomyolysis and myopathy have emerged, through decades of clinical experience, as the main AEs associated with statin treatment. These AEs are rare at the approved dose range, but increasing doses, interactions with other medications and genetic predisposition can increase the risk of a patient experiencing these events.55 Although the incidence of rhabdomyolysis in patients taking statin monotherapy is low (approximately 3 hospitalised cases per million person-years), it is potentially fatal.55 Myalgias have been reported in up to 10% of patients receiving statins in clinical practice55,56 and higher rates up to 18% were seen with high-intensity statins.56 In terms of musculoskeletal events, as with the safety profile of statins in general, the risk of AEs is impacted minimally by the addition of ezetimibe.57

Musculoskeletal events such as back pain or arthralgia are also among the most common AEs reported across clinical studies of anti-PCSK9 antibodies. Data from two large pooled analyses, one of phase 3 alirocumab trials and another of phase 2 and 3 open-label extension studies of evolocumab, showed that the incidence of back pain was 5.3% and 4.2%, respectively (placebo or standard of care: 6.0%
TABLE 1 LDL-C goal achievement (according to the 2011 EAS/ESC guidelines) with alirocumab and evolocumab, by patient population

| Study                | Anti-PCSK9 antibody group | Comparator group | Study duration (weeks) | Concomitant therapy (all treatment arms) |
|----------------------|---------------------------|------------------|------------------------|----------------------------------------|
| **Heterozygous FH**  |                           |                  |                        |                                        |
| ODYSSEY FH I \(^{30}\) | Alirocumab 75 mg Q2W:     | Placebo: 2.4%    | 78                     | 82.7%-85.3% received high-intensity statin therapy (atorvastatin 40-80 mg QD, rosuvastatin 20-40 mg QD or simvastatin 80 mg QD) 56.0%-59.5% received ezetimibe |
|                      | 72.2%                     |                  |                        |                                        |
| ODYSSEY FH II \(^{30}\) | Alirocumab 75 mg Q2W:     | Placebo: 11.3%   | 78                     | 86.8%-91.5% received high-intensity statin therapy (atorvastatin 40-80 mg QD, rosuvastatin 20-40 mg QD or simvastatin 80 mg QD) 64.6%-67.1% received ezetimibe |
|                      | 81.4%                     |                  |                        |                                        |
| ODYSSEY HIGH FH\(^{34,a}\) | Alirocumab 150 mg Q2W:   | Placebo: 5.7%    | 24                     | 100% received maximally tolerated statin ± other LLT |
|                      | 41.0%                     |                  |                        |                                        |
| RUTHERFORD-2\(^{40}\) | Evolocumab 140 mg Q2W:    | Placebo: 2%      | 12                     | 100% received statins: 87% received high-intensity statin (simvastatin 80 mg QD, atorvastatin ≥40 mg QD, rosuvastatin ≥20 mg QD or any dose of statin together with ezetimibe) 62% received ezetimibe |
|                      | 68.0%                     |                  |                        |                                        |
|                      | Evolocumab 420 mg QM:     |                  |                        |                                        |
|                      | 63.0%                     |                  |                        |                                        |
| **Type 2 diabetes mellitus** |                           |                  |                        |                                        |
| Pooled meta-analysis of four studies \(^{45,79}\) | Evolocumab 140 mg Q2W:    | Ezetimibe 10 mg + placebo Q2W: 36.0% | 12 | MENDEL-2\(^{38}\): no background therapy LAPLACE-2\(^{20}\): 29% received high-intensity statin therapy (atorvastatin >40 mg QD or rosuvastatin >20 mg QD, simvastatin 80 mg QD or any statin plus ezetimibe), 41% received non-intensive statin therapy, 30% received no statin therapy RUTHERFORD-2\(^{40}\): 87% received high-intensity statin therapy (simvastatin 80 mg QD, atorvastatin ≥40 mg QD, rosuvastatin ≥20 mg QD or any dose of statin together with ezetimibe 10 mg QD), 62% received ezetimibe 10 mg QD GAUSS-2\(^{42}\): 33% received LLT, 18% received low-dose statin therapy |
|                      | 88.0%                     | Ezetimibe 10 mg + placebo Q2W: 29.0% |                        |                                        |
|                      | Evolocumab 420 mg Q4W:    | Ezetimibe 10 mg + placebo QM: 23.0% |                        |                                        |
|                      | 87.0%                     | Ezetimibe 10 mg + placebo QM: 16.0% |                        |                                        |
| **Low-to-high CV risk** |                           |                  |                        |                                        |
| DESCARTES\(^{38,b}\) | Evolocumab 420 mg Q4W + diet + background LLT: 83.6% | Placebo Q4W+ diet + background LLT: 3.2% | 52 | None |
|                      | Evolocumab 420 mg Q4W + diet + atorvastatin 10 mg QD: 90.1% | Placebo Q4W + diet + atorvastatin 10 mg QD: 5.3% |                        |                                        |
|                      | Evolocumab 420 mg Q4W + diet + atorvastatin 80 mg QD: 80.8% | Placebo Q4W + diet + atorvastatin 80 mg QD: 6.1% |                        |                                        |
|                      | Evolocumab 420 mg Q4W + diet + atorvastatin 80 mg QD + ezetimibe 10 mg QD: 67.0% | Placebo Q4W + diet + atorvastatin 80 mg QD + ezetimibe 10 mg: 11.1% |                        |                                        |
|                      | Overall: 82.3%            | Overall: 6.4%    |                        |                                        |

*Goal defined as LDL-C <70 mg/dL (<1.8 mmol/L) for all patients*
TABLE 1 (Continued)

| Study                     | Anti-PCSK9 antibody group | Comparator group | Study duration (weeks) | Concomitant therapy (all treatment arms) |
|---------------------------|---------------------------|------------------|------------------------|------------------------------------------|
| **Moderate-to-very high CV risk** |                           |                  |                        |                                          |
| ODYSSEY MONO[^4^]c        | Alirocumab 75 mg Q2W (up titrated to 150 mg Q2W): 65.0% | Ezetimibe: 10 mg QD: 2%-3% | 24 | None |
| ODYSSEY CHOICE I[^5^]d    | Alirocumab 300 mg Q4W: 78.9% Alirocumab 300 mg Q4W + statin: 85.2% Alirocumab 75 mg Q2W: 84.9% Alirocumab 75 mg Q2W + statin: 82.5% | Placebo: 9.4% Placebo + statin: 22.2% | 24 | No statin group: 0–1.4% received atorvastatin, rosuvastatin or simvastatin; 32.4%-45.2% received other LLT Statin group: 99.4%-100% received atorvastatin, rosuvastatin or simvastatin 32.4%-45.2% received other LLT |
| ODYSSEY CHOICE II[^6^]d   | Alirocumab 150 mg Q4W: 63.9% Alirocumab 75 mg Q2W: 70.3% | Placebo Q2W: 1.8% | 24 | 30.2%-34.5% received diet alone 59.3%-60.3% received ezetimibe 5.2%-10.3% received fenofibrate |
| **High CV risk**          |                           |                  |                        |                                          |
| ODYSSEY COMBO I[^7^]e     | Alirocumab 75 mg Q2W: 75.0% | Placebo: 9% | 24 | 99.5–100% received statins (high dose: 61.7%-64.5%; atorvastatin 40-80 mg QD or rosuvastatin 20-40 mg QD or simvastatin 80 mg QD) 7.2%-10.3% received ezetimibe 38.3%-49.5% received other LLT |
| ODYSSEY COMBO II[^8^]f    | Alirocumab 75 mg Q2W: 77.0% | Ezetimibe 10 mg QD: 45.6% | 24 | 99.8%-100% received statins 66.4%-66.8% received high-intensity statin therapy (atorvastatin 40-80 mg QD or rosuvastatin 20-40 mg QD) |
| ODYSSEY LONG TERM[^9^,g]  | Alirocumab 150 mg Q2W (high or very high risk): 80.7% Regardless of risk: 79.3% | Placebo: (high or very high risk): 8.5% Regardless of risk: 8.0% | 24 (secondary end-point) | 100% received maximum tolerated daily statin therapy ≥99.9% received statins 46.7%-46.8% received high-intensity therapy (atorvastatin 40-80 mg QD, rosuvastatin 20-40 mg QD or simvastatin 80 mg QD) 13.9%-15.0% received ezetimibe 27.9%-28.1% received other LLT |
| YUKAWA-2[^2^]h            | Evolocumab 140 mg Q2W + atorvastatin 5 mg QD: 98.0%-100% Evolocumab 420 QM + atorvastatin 5 mg QD: 96.0%-100% Evolocumab 140 Q2W + atorvastatin 20 mg QD: 96.0%-100% Evolocumab 420 mg QM + atorvastatin 20 mg QD: 98.0%-100% Goal defined as LDL-C <70 mg/dL (<1.8 mmol/L) for all patients | Placebo Q2W + atorvastatin 5 mg QD: 0.0%-29.0% Placebo QM + atorvastatin 5 mg QD: 4.0%-42.0% Placebo Q2W + atorvastatin 20 mg QD: 20.0%-59.0% Placebo QM + atorvastatin 20 mg QD: 20.0%-88.0% | 12 | 100% received statins (atorvastatin 5 mg or 20 mg QD) |
**TABLE 1** (Continued)

| Study | Anti-PCSK9 antibody group | Comparator group | Study duration (weeks) | Concomitant therapy (all treatment arms) |
|-------|--------------------------|------------------|------------------------|----------------------------------------|
| **High-to-very high CV risk** | | | | |
| ODYSSEY OPTIONS I \(^{27}\) | Alirocumab 75 mg Q2W + atorvastatin 20/40 mg QD: 84.6%-87.2% | Ezetimibe 10 mg QD + atorvastatin 20/40 mg QD: 65.1%-68.4% | 24 | 100% received statins (atorvastatin 20 mg or 40 mg QD) |
| ODYSSEY OPTIONS II \(^{29}\) | Alirocumab 75 mg Q2W + rosvastatin 10/20 mg QD: 66.7%-84.9% | Ezetimibe 10 mg QD + rosvastatin 10/20 mg QD: 43.1%-57.2% | 24 | 100% received statins (rosuvastatin 10 mg or 20 mg QD) |
| **Statin intolerant** | | | | |
| ODYSSEY ALTERNATIVE \(^{32}\) | Alirocumab 75 mg Q2W (up titrated to 150 mg Q2W): 41.9%-51.2% | Ezetimibe 10 mg QD: 4.4%-5.6% | 24 | 37.3%-54.0% received LLT other than statins |
| GAUSS-2 \(^{42}\) | Evolocumab 140 mg Q2W + placebo QD (week 12): 50.5% Evolocumab 420 mg QM + placebo QD (week 12): 37.5% Goal defined as LDL-C \(<70 \text{ mg/dL} (<1.8 \text{ mmol/L})\) for all patients | Ezetimibe 10 mg QD + placebo Q2W: 2.0% Ezetimibe 10 mg QD + placebo QM: 0.0% | 12 | 33% received any LLT (18% low dose statin) |

Only studies that reported LDL-C goal achievement are included. \(^a\)Patients had baseline LDL-C levels of \(\geq 160 \text{ mg/dL} (4.1 \text{ mmol/L})\) despite maximally tolerated statin or other LLT. \(^b\)CV risk was determined according to NCEP ATP III guidelines. High risk: 26.0% and 26.6% of patients receiving evolocumab and placebo, respectively. Moderately high risk: 9.3% and 9.6% of patients receiving evolocumab and placebo, respectively. Moderate risk: 33.9% and 32.1% of patients receiving evolocumab and placebo, respectively. Low risk: 30.7% and 32.1% of patients receiving evolocumab and placebo, respectively. \(^c\)Mod- erate CV risk: 10-year fatal CVD risk SCORE of \(\geq 1\%\) and \(<5\%. High CV risk: presence of at least one of the following—10-year fatal CVD risk SCORE \(\geq 5\%; moderate chronic kidney disease; type 1 or type 2 diabetes mellitus without target organ damage; or FH. Very high CV risk: presence of one or more of the following—history of CHD, ischaemic stroke, peripheral artery disease, transient ischaemic attack, abdominal aortic aneurysm or carotid artery occlusion >50% without symptoms; carotid endarterectomy or carotid artery stent procedure; renal artery stenosis or renal artery stent procedure; or type 1 or type 2 diabetes mellitus with target organ damage. \(^d\)CV risk definition not reported. \(^e\)High CV risk: LDL-C \(\geq 70 \text{ mg/dL} (\geq 1.8 \text{ mmol/L})\) and established CVD or LDL-C \(\geq 100 \text{ mg/dL} (\geq 2.6 \text{ mmol/L})\) with CHD risk equivalents (eg, diabetes mellitus with other risk factors or chronic kidney disease) and LDL-C \(\geq 70 \text{ mg/dL} (\geq 1.8 \text{ mmol/L})\). \(^f\)High CV risk: heterozygous familial hypercholesterolaemia or established CHD or a CHD risk equivalent (ischaemic stroke, peripheral artery disease, moderate chronic kidney disease, or diabetes mellitus plus \(\geq 2\) additional risk factors). \(^g\)17.7% of patients had heterozygous HF. \(^h\)High CV was determined according to Japanese Atherosclerosis Society (JAS) classification criteria. Goal defined as LDL-C \(<100 \text{ mg/dL} (\leq 2.6 \text{ mmol/L})\); a more stringent goal of LDL-C \(<70 \text{ mg/dL} (\leq 1.8 \text{ mmol/L})\) was also assessed. Very high CV risk: a history of CVD, including CHD, or type 2 diabetes mellitus with target organ damage and LDL-C \(\geq 70 \text{ mg/dL} (\geq 1.8 \text{ mmol/L})\). High CV risk: no history of CVD or CHD but with other risk factors as follows—10-year fatal CVD risk SCORE \(\geq 5\%; moderate chronic kidney disease; type 2 diabetes mellitus with no target organ damage; and LDL-C \(\geq 100 \text{ mg/dL} (\geq 2.6 \text{ mmol/L})\). CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; FH, familial hypercholesterolaemia; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; PCSK9, proprotein convertase subtilisin/kexin type 9; QD, every day; Q2W, every 2 weeks; Q4W, every 4 weeks; QM, every month; SCORE, Systemic Coronary Risk Evaluation.
and 3.7%, respectively) and that arthralgia occurred in 5.1% and 4.8% of patients, respectively (placebo or standard of care: 6.5% and 3.2%, respectively). Although there is some variation in the incidences of muscle-related AEs reported in trials of anti-PCSK9 antibodies, in general these are balanced between study arms. In the pooled analysis of open-label extension studies of evolocumab, the incidence of muscle-related AEs was 6.5% with evolocumab and 6.1% with standard of care. 59 With alirocumab, the incidence was slightly higher because muscle-related events were grouped with connective tissue disorders in the long-term follow-up trial ODYSSEY LONG TERM, but remained balanced with the placebo arm (alirocumab: 30.1%; placebo: 30.7%). 64 Myalgia occurred in 3.0% of patients receiving evolocumab and 2.9% of those receiving the standard of care 59 and in the long-term follow-up trial of alirocumab (ODYSSEY LONG TERM), the incidence of myalgia was 5.4% with alirocumab compared with 2.9% with placebo. 32 In the open-label extension studies of evolocumab, elevated creatine kinase levels (>5×ULN) were observed in 0.6% of patients receiving evolocumab (standard of care, 1.2%). 59 In ODYSSEY LONG TERM, 3.7% of individuals receiving alirocumab and 4.9% of those receiving placebo had elevated levels of creatinine kinase (>3×ULN). 33 For patients who were statin-intolerant, elevated creatine kinase levels (>3×ULN) were observed in 2.4% of patients receiving alirocumab and in 1.6% and 4.8% of patients receiving ezetimibe and atorvastatin, respectively. 32 In GAUSS-2, 2.0% of statin-intolerant patients receiving evolocumab 420 mg every month had elevated creatinine kinase levels (>5×ULN) compared with 0% in the ezetimibe group. Elevated levels of creatine kinase were not observed in the evolocumab 140 mg every 2 weeks group, but were seen in the corresponding ezetimibe group (6%). 42

There are case reports documenting mild and reversible impaired cognitive function in patients receiving statins. 60 The results of several large meta-analyses, however, seem to suggest no increase in risk, and a causal link with statin treatment has not been established. 61 In 2014, the US Food and Drug Administration (FDA) requested that the feasibility of including analysis of neurocognitive AEs in late-stage clinical trials of anti-PCSK9 antibodies be assessed. 62 In the randomised double-blinded ODYSSEY LONG TERM trial of alirocumab in combination with statins, the rate of neurocognitive AEs at week 78 was not significantly different between the alirocumab and placebo arms (1.2% vs 0.5%, respectively; P = .17). 32 In a pooled analysis of two open-label randomised trials (OSLER-1 and OSLER-2), the incidences of neurocognitive events in patients treated with evolocumab plus standard therapy versus standard therapy alone were 0.9% and 0.3%, respectively, at week 48. 41 No association has been found between the rate of these AEs and LDL-C reduction in this or other studies. 33,41,59 However, a recent meta-analysis of 13 083 patients in phase 2 and 3 trials reported that anti-PCSK9 antibodies were associated with an increased incidence of neurocognitive AEs compared with placebo (odds ratio [OR] 2.34; P = .02). 63 This meta-analysis was based on 55 neurocognitive events and resulted in a number needed to harm of 269 associated with a broad confidence interval (CI) ranging from 93 to 3257. 64 The methodology of this meta-analysis was criticised as some patients were counted more than once, owing to their participation in both the OSLER studies and the parent studies. 65 The effect of anti-PCSK9 antibodies on neurocognitive events or cognitive function remains unclear owing to the fact that the blood-brain barrier cannot be crossed by monoclonal antibodies and that the brain produces its cholesterol by de novo synthesis. 66 A 4-year neurocognitive substudy of the FOURIER trial (EBBINGHAUS) is ongoing to prospectively assess the effects of evolocumab on specific cognitive aspects using a standardised, sensitive and validated test instrument.

Other potential AEs with statins include elevated liver enzymes, which may occur more frequently in patients receiving ezetimibe–statin combination therapy than with statin monotherapy. 57 Differences in levels of liver enzymes between anti-PCSK9 antibody groups and control groups have not yet been observed in clinical studies. With alirocumab, elevated levels (>3×ULN) of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were observed in 1.8% and 1.4% of patients, respectively in the ODYSSEY LONG TERM study (placebo 2.1% and 2.3%, respectively). 33 In the combined analysis of open-label extension studies of evolocumab, elevated levels of ALT/AST were found in 1.0% of patients receiving evolocumab and in 1.2% of those receiving the standard of care. 41,43,59

Limited data are available on the use of anti-PCSK9 antibodies in patients with hepatic or renal impairment. However, anti-PCSK9 antibodies are proteins and are therefore not expected to be metabolised by the liver or kidneys; hence, no effects on the liver or kidneys are expected. For evolocumab, a small pharmacokinetics study reported no differences in efficacy or safety between healthy volunteers and in patients with mild or moderate hepatic impairment. 64 Another evolocumab study reported no differences in LDL-C lowering or safety among patients with normal renal function and those with severe renal impairment or end-stage renal disease. 67 The recently published FOURIER study included patients with renal impairment (glomerular filtration rate as low as 20 mL/min) 26 and subgroup analyses examining the safety and efficacy of evolocumab in this population are expected. For alirocumab, a pooled analysis of data from patients with type 2 diabetes mellitus and chronic kidney disease enrolled in phase 3 trials showed no difference in LDL-C lowering or safety signals between patients with mild or moderate kidney disease. Furthermore, no effect on chronic kidney disease progression was observed. 58 Although larger studies in patients with hepatic or renal impairment are warranted, current evidence supports the use of evolocumab without dose adjustments in these patients. 32 Similarly, with alirocumab, dose adjustments are not required for patients with renal or hepatic impairment, although no data are currently available for patients with hepatic impairment. 81 The systematic review of phase 3 data for alirocumab and evolocumab reported that, aside from musculoskeletal events, the most common AEs were nasopharyngitis and upper respiratory tract infections. 18 Injection site reactions were reported at similar frequencies in evolocumab and control treatment arms, whilst studies of alirocumab varied in whether injection site reactions occurred more often with the anti-PCSK9 agent or comparators. 18 Treatment-emergent anti-drug antibodies were rare, but were reported in five alirocumab studies (highest incidence 12%), and in one patient in a single evolocumab
study. Treatment-emergent neutralising antibodies were reported in a small number of patients (<1%) in four of the alirocumab studies that were included in the anti-PCSK9 systematic review, but this did not impact on efficacy or safety. Of the evolocumab studies that assessed the formation of neutralising antibodies, such antibodies were not detected in any patient receiving evolocumab. Furthermore, no neutralising antibodies were detected in the pooled analysis of over 6000 patients who had participated in evolocumab clinical trials. Serious AEs, treatment-related discontinuations and discontinuations owing to AEs were rare with anti-PCSK9 antibody therapy.

Importantly, no significant differences in the incidence AEs, both overall and within each category of AE were observed in patients achieving very low levels of LDL-C and those with higher LDL-C levels with evolocumab or with alirocumab.

### 3.4 What benefits can be expected when using anti-PCSK9 antibodies?

There is considerable evidence for a causal relationship between LDL-C reduction and a decrease in the number of CVEs. The reduction in CV risk may, however, be specific to the mechanism of action of a drug: agents that increase the number of LDL receptors, such as statins, anti-PCSK9 antibodies and ezetimibe, are likely to reduce CV risk. Drugs with a different mechanism of action, such as inhibitors of the cholesteryl ester transfer protein (CETP), decrease LDL-C without any proven evidence of CVE risk reduction. The ongoing REVEAL trial is investigating the effect of anacetrapib, a CETP inhibitor, on CV risk.

In 2005, the CTT’s collaboration published a meta-analysis in which data from over 90 000 patients were analysed to assess the effect of statin therapy on CV risk reduction. An update to this meta-analysis assessing the impact of more or less intensive statin therapy was published in 2010. Both studies found that a 40 mg/dL (1 mmol/L) reduction in LDL-C reduced the annual rate of major CVEs by approximately a fifth (21% in the 2005 study and 22% in the later study). Crucially, the 2010 meta-analysis demonstrated that, within the cholesterol range studied, the size of the proportional reduction in major CVEs was directly proportional to the absolute LDL reduction achieved. It was suggested that reducing LDL-C by 80-120 mg/dL (2-3 mmol/L; as seen with anti-PCSK9 antibodies) would reduce risk by 40%-50%.

More recently, the double-blind, randomised IMPROVE-IT trial compared
statin plus ezetimibe with statin monotherapy in 18 144 patients who had been hospitalised for acute coronary syndrome. The primary endpoint of this study was a composite of CV death, major coronary event and non-fatal stroke. Adding ezetimibe to statin therapy in patients with mean LDL-C levels within guideline recommendations (<70 mg/dL [<1.8 mmol/L]) resulted in a further 12.8 mg/dL (0.33 mmol/L) reduction in LDL-C compared with statin alone (based on imputation for missing data) after a 7 year follow-up. This reduction in risk is consistent with that expected from the CTT meta-analysis: a 38.7 mg/dL (1 mmol/L) LDL-C reduction leads to a 22% reduction in CVEs; therefore a 12.8 mg/dL (0.33 mmol/L) LDL-C reduction is expected to reduce CVEs by 7.9%. This current study has demonstrated that adding LLTs to statins can reduce the risk of CVEs, consistent with the conclusion of the CTT meta-analysis. The nature of the relationship between intensive LDL-C lowering and CVE rates warrants further investigation.

The lowering of LDL-C achieved with anti-PCSK9 antibody therapy may also reduce CV risk. Over periods of a year or more, alirocumab or evolocumab have been reported to significantly reduce the rate of CVEs when added to standard therapy (Table 2). Although these studies were not designed or powered to examine efficacy in terms of CV benefit, it is interesting to observe that the reductions in incidence of CVEs with anti-PCSK9 antibody therapy fit well with theoretical reductions predicted on the basis of data from the CTT meta-analysis. Based on a predicted reduction in CVE rate of 22% for every 38.7 mg/dL (1 mmol/L) reduction in LDL-C in statin and ezetimibe trials, and the LDL-C reductions reported (at 24 and 12 weeks in two anti-PCSK9 antibody trials, ODYSSEY LONG TERM and OSLER-1 and -2, respectively), a reduction of around 40% in major CVEs would be expected. Notably, the observed reductions in major CVEs in clinical trials of 48% and 53% with alirocumab and evolocumab, respectively (Table 2), even slightly surmounted the expected decreases. The FOURIER trial, in which patients with atherosclerotic cardiovascular disease and elevated LDL-C levels were treated with either placebo or evolocumab (on a background of maximally tolerated statins), is the first to report on the impact of anti-PCSK9 therapies on the incidence of CVEs. After a median follow-up of 2.2 years, compared with placebo evolocumab reduced LDL-C levels by 59% and reduced the relative risk of the composite CVE end-point (CV death, myocardial infarction, stroke, hospitalisation for unstable angina and coronary revascularisation) by 15%. The magnitude of risk reduction increased over time from 12% in the first 12 months to 19% beyond the first year. This reduction is largely consistent with the benefit observed with statins, based on the per-micromole-per-litre reductions in LDL-C levels observed in the CTT study.

**TABLE 3** Predicted 10-year NNT with an anti-PCSK9 antibody (with a predicted 60% LDL-C reduction from baseline) to prevent 1 CVE for various absolute 10-year risk of major CVEs and various baseline LDL-C levels

| Absolute 10-year risk of a major CVE | Baseline LDL-C levels, mg/dL (mmol/L) | Predicted LDL-C reductions achieved with anti-PCSK9 antibody treatment, mg/dL (mmol/L) | Predicted LDL-C levels following anti-PCSK9 antibody treatment, mg/dL (mmol/L) | Predicted 10-year absolute risk of a major CVE with anti-PCSK9 antibody treatment | 10-year NNT to prevent 1 CVE |
|--------------------------------------|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|-------------------------|
| 60%                                  | 200 (5.2)                            | 120 (3.1)                        | 80 (2.1)                         | 28%                              | 4                      |
|                                      | 160 (4.1)                            | 96 (2.5)                         | 64 (1.7)                         | 32%                              | 4                      |
|                                      | 120 (3.1)                            | 72 (1.7)                         | 48 (1.2)                         | 38%                              | 5                      |
|                                      | 80 (2.1)                             | 48 (1.2)                         | 32 (0.83)                        | 44%                              | 6                      |
| 30%                                  | 200 (5.2)                            | 120 (3.1)                        | 80 (2.1)                         | 14%                              | 6                      |
|                                      | 160 (4.1)                            | 96 (2.5)                         | 64 (1.7)                         | 16%                              | 7                      |
|                                      | 120 (3.1)                            | 72 (1.7)                         | 48 (1.2)                         | 19%                              | 9                      |
|                                      | 80 (2.1)                             | 48 (1.2)                         | 32 (0.83)                        | 22%                              | 13                     |
| 15%                                  | 200 (5.2)                            | 120 (3.1)                        | 80 (2.1)                         | 7%                               | 13                     |
|                                      | 160 (4.1)                            | 96 (2.5)                         | 64 (1.7)                         | 8%                               | 15                     |
|                                      | 120 (3.1)                            | 72 (1.7)                         | 48 (1.2)                         | 9%                               | 18                     |
|                                      | 80 (2.1)                             | 48 (1.2)                         | 32 (0.83)                        | 11%                              | 26                     |

CTT, Cholesterol Treatment Trialists; CVE, cardiovascular event; LDL-C, low-density lipoprotein-cholesterol; NNT, number needed to treat; PCSK9, proprotein convertase subtilisin/kexin type 9. Patients may or may not be receiving LLT. Using data from the CTT meta-analysis. NNT for 10 years to prevent one CVE=100/((1−0.78n)×10-year CVE risk in %), where n=LDL-C reduction in mmol/L and 0.78 represents the decrease in CVD risk for each 1 mmol/L reduction in LDL-C.

**TABLE 4** Typical characteristics of patients in secondary prevention with high LDL-C levels despite receiving maximally tolerated LLT who may be considered for treatment with anti-PCSK9 antibodies. At least two of the following factors should be present

| Familial hypercholesterolaemia |
|----------------------------------|
| Previous myocardial infarction, progressive CVD or atherosclerosis |
| Type 2 diabetes mellitus |
| Moderate-to-severe chronic kidney disease (GFR<60 mL/min/1.73 m²) |
| Heart failure (New York Heart Association classification III-IV) |

CVD, cardiovascular disease; GFR, glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PCSK9, proprotein convertase subtilisin/kexin type 9.
3.5 | Hypothetical patient cases

We have used the hypothetical principles of anti-PCSK9 antibody-mediated LDL-C lowering (assuming that the same benefit is observed as with statin and ezetimibe) to predict 10-year NNTs with anti-PCSK9 antibodies to prevent one CVE for patients with varying baseline LDL-C levels and absolute 10-year CVE risks (Figure 2). As the 10-year risk of a CVE increased, the NNT to prevent one

### TABLE 5  
Predicted outcomes in a hypothetical case of a 54-year old male patient who had previously experienced a myocardial infarction and has very high baseline LDL-C levels (scenario A) despite receiving maximally tolerated statin plus ezetimibe and (scenario B) under ezetimibe treatment in the scenario of statin intolerance.

On the basis of the overall results from ODYSSEY COMBO II, an absolute reduction in LDL-C levels of at least 100 mg/dL (2.6 mmol/L) would be anticipated in scenario A following the addition of an anti-PCSK9 antibody to a statin plus ezetimibe. Using estimates from the CTT trial, this would translate into a 47% reduction in relative risk of major CVEs over 10 years. Assuming a predicted 10-year absolute risk of CV death of 20% for this patient (Figure 3), the use of ezetimibe plus maximally tolerated statin would half this risk (9%). Anti-PCSK9 antibody as an add-on therapy would further reduce this risk to 5%. In terms of absolute 10-year risk of a major CVE (fatal and non-fatal), an anti-PCSK9 antibody with ezetimibe and maximally tolerated statin would reduce the 10-year absolute CVE risk from 60% to 15%. Addition of an anti-PCSK9 antibody to statin and ezetimibe gives a NNT of 8.

We have applied the same principles to another scenario (scenario B). This patient is similar to that described above, but has lower baseline LDL-C (191 mg/dL (4.9 mmol/L)) and is statin intolerant. In this case, and using data from the ODYSSEY ALTERNATIVE trial and the CTT meta-analysis, ezetimibe slightly reduced the 10-year absolute risk of CV death from 20% to 17%; treatment with anti-PCSK9 antibodies was predicted to drastically reduce this risk to 8% (a reduction in predicted absolute 10-year risk of a CVE from 60% to 24%). The NNT for the addition of an anti-PCSK9 antibody to ezetimibe therapy was 4, compared with 10 with ezetimibe alone. In both scenarios, it was assumed that treatments were well tolerated and that patients were adherent to treatment.

#### Scenario A

| Parameter                                | Baseline | Ezetimibe + maximally tolerated statin | Anti-PCSK9 antibody + ezetimibe + maximally tolerated statin |
|------------------------------------------|----------|----------------------------------------|-------------------------------------------------------------|
| LDL-C, mg/dL (mmol/L)                    | 261 (6.7) | 141 (3.6)                              | 41 (1.1)                                                    |
| Predicted reduction in LDL-C (% change vs previous therapy) | –        | −46%                                   | −71%                                                        |
| Predicted reduction in LDL-C, mg/dL (mmol/L) | –        | 120 (3.1)                              | 100 (2.6)                                                   |
| Predicted annual risk reduction in major CVEs (%) | –        | −54% vs baseline                       | −47% vs ezetimibe + statins 76% vs baseline                 |
| Predicted absolute 10-year risk of a major CVE (%) | 60%      | 28%                                    | 15%                                                         |
| Predicted 10-year risk of CV death (%) | 20%      | 9%                                     | 5%                                                          |
| NNT for 10 years to prevent one CVE | –        | 4 vs baseline                          | 3 vs baseline 8 vs previous treatment                       |

#### Scenario B: Statin intolerance

| Parameter                                | Baseline without statins | Ezetimibe alone | Anti-PCSK9 antibody + ezetimibe |
|------------------------------------------|--------------------------|-----------------|--------------------------------|
| LDL-C, mg/dL (mmol/L)                    | 191 (4.9)                | 163 (4.2)       | 51 (1.3)                       |
| Predicted reduction in LDL-C (% change vs previous therapy) | –        | 15%             | 69%                           |
| Predicted reduction in LDL-C, mg/dL (mmol/L) vs previous therapy | –        | 28 (0.72)       | 112 (2.9)                     |
| Predicted annual risk reduction in major CVEs (%) vs previous therapy | –        | 16% vs baseline | 51% vs ezetimibe 59% vs baseline |
| Predicted absolute 10-year risk of a major CVE (%) | 60%      | 50%             | 24%                           |
| Predicted 10-year risk of CV death (%) | 20%      | 17%             | 8%                            |
| NNT for 10 years to prevent one CVE | –        | 11              | 3 vs baseline 4 vs ezetimibe |

CTT, Cholesterol Treatment Trialists; CV, cardiovascular; CVE, cardiovascular event; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9. aPredicted reductions in LDL-C are based on data from the ODYSSEY COMBO II trial. bPredicted risk reduction in CVEs calculated based on data from the CTT meta-analysis. Absolute 10-year risk of a major CVE=baseline risk×(1−risk reduction), as calculated on Figure 2. cNNT for 10 years to prevent one CVE=100/([1−0.78n]×10-year CVE risk in %), where n=LDL-C reduction in mmol/L and 0.78 represents the decrease in CVDrisk for each 1 mmol/L reduction in LDL-C. dThe 10-year NNT was calculated using the reduction in LDL-C from baseline. eThe 10-year NNT was calculated when adding an anti-PCSK9 antibody to previous therapy.
CVE decreased. For example, for patients with high baseline LDL-C (160 mg/dL [4.1 mmol/L]), an anti-PCSK9 antibody is expected to decrease LDL-C level by 96 mg/dL (2.5 mmol/L; ie, 60% LDL reduction). If the patient has a 10-year absolute risk of a CVE of 15%, the predicted 10-year NNT to prevent one CVE was 15. At the same baseline LDL-C level, the 10-year NNT to prevent one CVE was less than 8 if the 10-year risk of a CVE was higher than 30%. For patients with very high 10-year CVE risk (above 30%) and LDL-C levels of 160 mg/dL (4.1 mmol/L) or more, the predicted 10-year NNT (ranging from 3 to 8) might be considered as very efficient. Predicted 10-year NNTs to prevent one CVE with anti-PCSK9 antibodies for patients with various baseline LDL-C levels and absolute 10-year risks of CVEs are shown in Table 3.

High 10-year absolute CVE risk (>30%) might be expected in some patients, such as: those in secondary prevention; those aged over 30 years with FH and other risk factors; those aged over 40 years and with type 2 diabetes mellitus and other risk factors or microalbuminuria; patients aged over 60 years without type 2 diabetes mellitus, but with multiple other risk factors and a SCORE (ie, 10-year risk of fatal CVD) of 10% or higher. Additional risk factors, such as smoking, high blood pressure, chronic kidney disease, family history of CVD, high levels of lipoprotein(a) or triglycerides may also contribute to increased CVE risk.3 These high-risk patient groups, together with those who are intolerant to statins, could benefit from anti-PCSK9 antibody treatment. However, with limited CV outcomes data, considering the costs associated with treatment, and in line with recent German recommendations, anti-PCSK9 antibody therapy should currently only be considered for secondary prevention in patients who have high LDL-C levels despite receiving maximally tolerated LLT and at least two of the following additional conditions: FH; previous myocardial infarction, progressive coronary heart disease or atherosclerosis; type 2 diabetes mellitus; moderate-to-severe chronic kidney disease (glomerular filtration rate <60 mL/min/1.73 m²); or heart failure (New York Heart Association classification III–IV) (Table 4).

Two examples of individuals who might visit their primary care physician and have a very high CVE risk and high levels of LDL-C are presented in Table 5 (see also Figure 3). These patients could be considered good candidates for anti-PCSK9 antibody therapy, either as monotherapy (in the case of statin intolerance) or in combination with other LLTs.

3.6 | Approved indications for alirocumab and evolocumab

Alirocumab and evolocumab have both been approved in Europe for use as an adjunct to diet in adults with primary hypercholesterolaemia (HeFH or non-familial hypercholesterolaemia) or mixed dyslipidaemia who do not achieve their LDL-C goal with other LLTs, or in those who are statin-intolerant.15,17 Evolocumab is also approved for use in combination with other LLTs in patients aged 12 years and older who have HoFH.15 Alirocumab is administered subcutaneously at a recommended starting dose of 75 mg once every 2 weeks or 300 mg once every 4 weeks, and it may be adjusted to 150 mg every 2 weeks.17 The dose of alirocumab can be tailored to the individual and may be up- or down-titrated as needed.15 Evolocumab is administered subcutaneously at a recommended dose of 140 mg every 2 weeks or 420 mg every month: both doses are considered clinically equivalent.15 For patients with HoFH, the dose of 420 mg every month may be up-titrated to 420 mg every 2 weeks if a clinically meaningful response is not achieved after 12 weeks of treatment.15 Owing to the high cost of these therapies, their use is expected to be limited to patients considered to be at very high risk, in whom LDL-C goals are not achieved with alternative maximally tolerated LLT.

4 | CONCLUSIONS AND CLINICAL IMPLICATIONS

Anti-PCSK9 antibodies are safe, well tolerated and efficacious in lowering LDL-C in a broad range of patient populations, and are suitable
as an add-on therapy to a statin or ezetimibe, or as a monotherapy for patients who are intolerant to statins. Current data suggest that they not only lower LDL-C, but also reduce the risk of CVEs. Studies that look at CV outcomes as a primary end-point are ongoing, and long-term data from outcome studies are awaited. These anti-PCSK9 antibodies are currently costly as they are intended for only a narrow population; however, once CV outcomes data are available the indication may expand and costs may therefore decrease. In Germany, the annual cost for treating one patient per year with an anti-PCSK9 antibody is approximately €8500. Therefore, the use of anti-PCSK9 antibodies may be limited by payers to patients with an extremely high CV risk and high LDL-C levels after exhausting all other LLTs at maximally tolerated doses (Table 4). According to this reasoning, approximately 60 000 patients would be eligible for anti-PCSK9 antibody treatment in Germany.

Safety data from phase 3 clinical trials of anti-PCSK9 antibodies have shown that they are associated with few serious AEs or treatment discontinuations and have a safety profile very comparable to placebo. Formal interaction testing is not required as monoclonal antibodies are not expected to have drug–drug interactions. Dose adjustments are not required for patients with mild to moderate renal or hepatic impairment. Additionally, dose adjustments are not needed for body weight making it simple for physicians to administer the correct dose. Following discontinuation of evolocumab, LDL-C levels gradually return to baseline over a period of up to 12 weeks (less rapidly than with statins), with no evidence of a rebound effect.

Estimates of 10-year NNT to prevent one CVE are well-supported by theoretical rationale and preliminary observations from clinical studies. However, we are aware that there may be limitations in using the hazard ratio observed with other LLTs and extrapolating these estimates to predict treatment effects of anti-PCSK9 antibodies. One of the limitations of calculating NNTs is the assumption that the treatment effect for statins compared with no statins will be the same as for anti-PCSK9 antibody plus statins compared with statin alone, which remains to be confirmed. Secondly, a 38.7 mg/dL (1 mmol/L) reduction in the context of the high baseline LDL-C levels seen in the CTT meta-analysis trials (143 mg/dL, 3.7 mmol/L) could have accounted for an overestimation of the NNT as compared with the effect of starting at a lower baseline of 88 mg/dL (2.3 mmol/L). The fact that anti-PCSK9 antibodies are add-on therapies to statins may also account for limitations in using the same NNT calculation for anti-PCSK9 antibodies and for statins alone. Because the LDL-C reductions in the IMPROVE-IT trial were small compared with reductions associated with anti-PCSK9 antibodies, caution is needed when extrapolating the effects observed in this trial to anti-PCSK9 antibodies. However, there is currently a strong level of evidence that the relationship between LDL-C level and CVE risk is similar between drugs that specifically target the LDL receptor pathway (eg, ezetimibe and various statins). This contrasts with other drugs that modulate LDL-C levels by other pathways (eg, fibrates and CETP inhibitors) with which no such relationship has been observed. Anti-PCSK9 antibodies primarily act on the LDL receptor pathways, therefore it would be reasonable to expect that the LDL-C reductions induced by these agents would have the same proportional effect on CVE risk as statins and ezetimibe. Furthermore, preliminary data demonstrating a CVE risk benefit in anti-PCSK9 antibody trials, albeit limited study durations [33,41] supports the predictions of CVE risk benefits made in this review.

While we await further data from anti-PCSK9 antibody trials that evaluate CV outcomes as primary end-points (rather than surrogate markers such as LDL-C levels), we propose that an anti-PCSK9 antibody should be considered for use in secondary prevention patients with high LDL-C levels despite receiving maximally tolerated LLT and at least two additional CVE risk factors.

ACKNOWLEDGEMENTS
Medical writing support was provided by Liz Hartfield PhD of Oxford PharmaGenesis, Oxford, UK, which was funded by Amgen (Europe) GmbH. Editorial support was provided by Carine Thual of Amgen (Europe) GmbH. Mary Elliott, biostatistician at Amgen Ltd, completed a quality check of the number-needed-to-treat calculations and methodology used in this manuscript. Alexander Dressel PhD, DACH Society for the Prevention of Cardiovascular Disease, Hamburg, provided statistical advice.

AUTHOR CONTRIBUTIONS
All authors contributed to the concept and design of the manuscript, drafting and critical revision of the article.

DISCLOSURES
U. Fraass is an employee of Amgen and owns stocks. R. Dent was an employee of Amgen at time of this work and owns stocks in Amgen and Esperion Therapeutics. I. Gouni-Berthold has received personal fees from Sanofi/Genzyme, Amgen, AstraZeneca, Bristol-Myers Squibb and Eli Lilly, O.S. Descamps has received grants, personal fees and non-financial support from Merck Sharp & Dohme, Amgen and Sanofi; grants and personal fees from AstraZeneca; grants from Pfizer; and personal fees from Abbott. W. März has received grants and personal fees from Aegerion Pharmaceuticals, Amgen, AstraZeneca, BASF, Danone Research, Numares AG, Pfizer, Sanofi/Genzyme and Siemens Diagnostics; grants from Abbott Diagnostics; personal fees from Alexion, Hoffmann-La Roche, Merck Sharp & Dohme, Sanofi; and has been employed by Synlab Holding Deutschland GmbH.

REFERENCES
1. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe – epidemiological update 2015. Eur Heart J. 2015;36:2696-2705.
2. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet No. 317, 2015. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed December 11, 2015.
3. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies
on Cardiovascular Disease Prevention in Clinical Practice (consti-
tuted by representatives of 10 societies and by invited experts); de-
veloped with the special contribution of the European Association
for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J.
2016;37:2315-2381.
4. O’Donnell CJ, Elosua R. Cardiovascular risk factors. Insights from
Framingham Heart Study, Rev Esp Cardiol. 2008;61:299-310.
5. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of
more intensive lowering of LDL cholesterol: a meta-analysis of
data from 17,000 participants in 26 randomised trials. Lancet.
2010;376:1670-1681.
6. Ford ES. Trends in the risk for coronary heart disease among adults
with diagnosed diabetes in the U.S.: findings from the National
Health and Nutrition Examination Survey, 1999–2008. Diabetes Care.
2011;34:1337-1343.
7. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardio-
vascular disease prevention in clinical practice (version 2012). The
Fifth Joint Task Force of the European Society of Cardiology and
Other Societies on Cardiovascular Disease Prevention in Clinical
Practice (constituted by representatives of nine societies and by in-
vited experts). Eur Heart J. 2012;33:1635-1701.
8. Aquilani R, Tramarin R, Pedretti RF, et al. Despite good compliance,
very low fat diet alone does not achieve recommended choles-
terol goals in outpatients with coronary heart disease. Eur Heart J.
1999;20:1020-1029.
9. Huninghake DB, Stein EA, Dujovne CA, et al. The efficacy of inten-
sive dietary therapy alone or combined with lovastatin in outpatients
with hypercholesterolemia. N Engl J Med. 1993;328:1213-1219.
10. Gitt AK, Dreux H, Feely J, et al. Persistent lipid abnormalities in statin-
treated patients and predictors of LDL-cholesterol goal achieve-
ment in clinical practice in Europe and Canada. Eur J Prev Cardiol.
2012;19:221-230.
11. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment
and all-cause mortality: a population-based cohort study. Arch Intern
Med. 2009;169:260-268.
12. Malingpat P, Gordon BR, Breslow JL. How do we improve patient
compliance and adherence to long-term statin therapy? Curr Atheroscler
Rep. 2013;15:291.
13. Seidah NG. Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibi-
tors in the treatment of hypercholesterolemia and other pathologies.
Curr Pharm Des. 2013;19:3161-3172.
14. Amgen Inc. REPATHA® (evolocumab) highlights of prescribing infor-
mation. http://pi.amgen.com/~/media/amgen/repository/sites/pi-am-
gen-com/repatha/repatha_pi_hcp_english.aspx. Accessed January 10,
2017.
15. Amgen. Repatha® (evolocumab) summary of product characteristics.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-._
Product_Information/human/003766/WC500191398.pdf. Accessed
May 19, 2016.
16. Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US. PRALUENT®
(alirocumab) highlights of prescribing information. http://products.sa-
nofi.us/praluent/praluent.pdf. Accessed. January 10, 2017.
17. Sanofi-Regeneron. Praluent® (alirocumab) summary of product charac-
teristics. http://www.regen.com/epca/docs/en_GB/document_library/EPAR_-.
Product_Information/human/003882/WC500194521.pdf. Accessed
May 19, 2016.
18. Gouni-Berthold I, Descamps OS, Fraass U, et al. Systematic re-
view of published phase 3 data on anti-PCSK9 monoclonal anti-
bodies in patients with hypercholesterolaemia. Br J Clin Pharmacol.
2016;82:1412-1443.
19. Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardio-
vascular risk, is important in deciding who should receive statin treat-
ment. Eur Heart J. 2015;36:2975-2983.
20. McQueen D. Numbers-needed-to-treat analysis. Adv Psychiatr Treat.
2011;17:158.
21. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to
statin therapy after acute coronary syndromes. N Engl J Med.
2015;372:2387-2397.
22. Ford I, Murray H, McCowen C, Packard CJ. Long-term safety and
efficacy of lowering low-density lipoprotein cholesterol with statin
therapy: 20-year follow-up of West of Scotland Coronary Prevention
Study. Circulation. 2016;133:1073-1080.
23. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of
patients randomized in the Scandinavian simvastatin survival study
(4S) of cholesterol lowering. Am J Cardiol. 2000;86:257-262.
24. Egan BM, Li J, White K, et al. ACC/AHA cholesterol guideline and im-
plications for healthy people 2020 cardiovascular disease prevention
goals. J Am Heart Assoc. 2013;2016:5.
25. Robinson JG, Ray K. Counterpoint: low-density lipoprotein choles-
terol targets are not needed in lipid treatment guidelines. Arterioscler
Thromb Vasc Biol. 2016;36:586-590.
26. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical
outcomes in patients with cardiovascular disease. N Engl J Med.
2017;376:1713-1722. https://doi.org/10.1056/nejma1615664.
27. Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atovas-
tatin versus other lipid treatment strategies: ODYSSEY OPTIONS I
randomized trial. J Clin Endocrinol Metab. 2015;100:3140-3148.
28. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab
in high cardiovascular risk patients with inadequately controlled
hypercholesterolaemia on maximally tolerated doses of statins: the
ODYSSEY COMBO II randomized controlled trial. Eur Heart J.
2015;36:1186-1194.
29. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding
alirocumab to rosuvastatin versus adding ezetimibe or doubling
the rosuvastatin dose in high cardiovascular-risk patients: the
ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:
138-146.
30. Kastelein JJ, Ginsberg RN, Langslet G, et al. ODYSSEY FH I and
FH II: 78 week results with alirocumab treatment in 735 patients
with heterozygous familial hypercholesterolaemia. Eur Heart J.
2015;36:2996-3003.
31. Kereakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of
the proprotein convertase subtilisin/kexin type 9 inhibitor aliro-
cumab among high cardiovascular risk patients on maximally tol-
erated statin therapy: the ODYSSEY COMBO I study. Am Heart J.
2015;169:906-915, e13.
32. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety
of alirocumab vs ezetimibe in statin-intolerant patients, with a statin
rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin
Lipidol. 2015;9:758-769.
33. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of ali-
cumab in reducing lipids in cardiovascular events. N Engl J Med.
2015;372:1489-1499.
34. Roth EM, Taskinen MR, Ginsberg RN, et al. Monotherapy with the
PCSK9 inhibitor alirocumab versus ezetimibe in patients with hy-
percholesterolaemia: results of a 24 week, double-blind, randomized
Phase 3 trial. Int J Cardiol. 2014;176:55-61.
35. Roth EM, Moriarty PM, Bergeron J, et al. A phase III randomized
trial evaluating alirocumab 300 mg every 4 weeks as mono-
therapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis.
2016;254:254-262.
36. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled
trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809-1819.
37. Kiyosue A, Honarpour N, Kurtz C, et al. A phase 3 study of evolo-
cumab (AMG 145) in statin-treated Japanese patients at high cardio-
vascular risk. Am J Cardiol. 2016;117:40-47.
38. Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 mono-
therapy for hypercholesterolemia: the MENDEL-2 randomized,
controlled phase III clinical trial of evolocumab. J Am Coll Cardiol.
2014;63:2531-2540.
39. Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab in patients with homozygous familial hypercholesterolemia (HoFH): interim results from the Trial Assessing Long-term Use of PCSK9 Inhibition in Subjects with Genetic LDL disorders (TAUSSIG) study. Presented at 17th International Symposium on Atherosclerosis, Amsterdam, Netherlands, 23–25 May, 2015.

40. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331-340.

41. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-1509.

42. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2016;63:2541-2548.

43. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341-350.

44. Ginsberg HN, Farnier M, Robinson JG, et al. Efficacy and safety of alirocumab: pooled analyses of 1048 individuals with diabetes mellitus from five placebo-controlled phase 3 studies of at least 52 weeks duration. Circulation. 2015;132:Abstr 17070.

45. Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4:403-410.

46. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.

47. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146-2157.

48. Lappegård K, Enebakk T, Thunhaug H, Hovland A. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL without lowering HDL cholesterol. Atherosclerosis. 2016;251:119-123.

49. Wang A, Richhariya A, Gandra SR, et al. Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc. 2016;5:e003294.

50. Stein E, Sampietro T, Santos R, et al. Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG). Presented at the 84th European Atherosclerosis Society Congress, Innsbruck, Austria May 29–June 1 2016.

51. Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J 2016;37:3588-3595. https://doi.org/10.1093/eurheartj/ehw388.

52. Bruckert E. Effect of alirocumab on the frequency of lipoprotein apheresis: a randomised phase III trial. Discussant review presented at the European Society of Cardiology Congress, Rome, Italy 27–31 August 2016.

53. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidemias: the Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818.

54. Ginsberg HN, Rader DJ, Ral FJ, et al. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Circulation. 2014;130.

55. Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf. 2012;3:133-144.

56. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther. 2005;19; 403-414.

57. Luo L, Yuan X, Huang W, et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Intern Med J. 2015;45:546-557.

58. Farnier M, Gaudet D, Valcheva V, et al. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY phase 3 clinical program trials. Int J Cardiol. 2016;223:750-757.

59. Toth PP, Descamps O, Genest J, et al. A pooled safety analysis of over 6000 patients from double-blind and open-label extension studies with evolocumab. J Am Coll Cardiol. 2016;67:1865.

60. US Food and Drug Administration. FDA expands advice on statin risk, 2014. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm. Accessed December 14, 2016.

61. Gauthier JM, Massicotte A. Statins and their effect on cognition: let's clear up the confusion. Can Pharm J (Ott). 2015;148:150-155.

62. Swiger KJ, Martin SS. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug Saf. 2015;38:519-526.

63. Lipinski MJ, Benedetto U, Escarego RO, et al. The impact of proprotein convertase subtilisin-kepin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016;37: 536-545.

64. Santos RD. Review: PCSK9 inhibitors reduce mortality but increase neurocognitive events in hypercholesterolaemia. Ann Intern Med. 2016;164;Jc31.

65. Kolodziejczak M, Navarese EP. Role of PCSK9 antibodies in cardiovascular disease: critical considerations of mortality and neurocognitive findings from the current literature. Atherosclerosis. 2016;247:189-192.

66. Gibbs JP, Slatter JG, Egbonu O, et al. Evaluation of evolocumab (AMG 145), a fully human anti-PCSK9 IgG2 monoclonal antibody, in subjects with hepatic impairment. J Clin Pharmacol. 2017;57: 513-523.

67. Lee E, Gibbs J, Wasserman SM, et al. Pharmacokinetics and pharmacodynamics of evolocumab in patients with renal impairment. Eur Heart J. 2016;37(Abstract Supplement):343.

68. Dwyer JP, Colhoun HM, Tinahones FJ, et al. Abstract 16850: Effect of alirocumab in patients with diabetic dyslipidemia and chronic kidney disease. Circulation. 2016;134:A16850.

69. Korzen MJ, Blom D, Giugliano RP, et al. Safety and tolerability of very low LDL-C levels in patients treated with 52 weeks of evolocumab (AMG 145). Circulation. 2014;130:A16865.

70. Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol. 2017;69:471-482.

71. Jarcho JA, Keaney JF Jr. Proof that lower is better – LDL cholesterol and IMPROVE-IT. N Engl J Med. 2015;372:2448-2450.

72. Grundy SM. Dyslipidemia in 2015: advances in treatment of dyslipidemia. Nat Rev Cardiol. 2016:13:74-75.

73. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2008;93:27-42.

74. ClinicalTrials.gov. REVEAL: Randomized EVaulation of the Effects of Anacetrapib Through Lipid-modification (REVEAL). https://clinicaltrials.gov/ct2/show/NCT01252953. Accessed May 20, 2016.

75. Baigent C, Keech A, Kearney P, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
76. März W, Scharnagl H, Gouni-Berthold I, et al. LDL-cholesterol: standards of treatment 2016 - a German perspective. Am J Cardiovasc Drugs. 2016;16:323-336.

77. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007;47:1104-1118.

78. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014;129:234-243.

79. Sattar NA, Djedjos CS, Robinson JG, et al. Efficacy and safety of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes. Diabetes. 2015;64:A68.

80. Robinson JG, Nedergaard BS, Rogers WI, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870-1882.

81. Stroes E, Guyton JR, Lepor N, et al. Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. J Am Heart Assoc. 2016;5:e003421.

How to cite this article: Descamps OS, Fraass U, Dent R, März W, Gouni-Berthold I. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. Int J Clin Pract. 2017;71:e12979. https://doi.org/10.1111/ijcp.12979